Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2015

View Archived Issues

Studies examine pain relief, abuse potential with kappa opioid receptor agonist CR-845

Redx Pharma unveils BTK inhibitor for leukemia and autoimmune disease

Complete responses seen with AU-011 in rabbit model of uveal melanoma

Astellas Pharma reports phase I results for ASKP-1240

Novel TTSP inhibitors shows promise for the treatment of influenza

Fluconazole capsules approved for vulvovaginal candidasis in Japan

Researchers use miRNA to improve toxicity of oncolytic Mengovirus

BMS and uniQure close gene therapy collaboration transaction

Cellceutix initiates phase II trial of brilacidin-OM to prevent oral mucositis

Bluebird bio to develop CAR T-cell therapies for cancer using Five Prime technology

ADC Therapeutics and LivTech sign antibody license agreement

Inovio and GeneOne partner to advance DNA vaccine for MERS into clinic

World MS Day: New target for MS yields impressive results in vivo; compound ready for trials

Eisai seeks Japanese approval of mecobalamin for ALS

Jinarc approved in Europe for autosomal dominant polycystic kidney disease

Theravance grants SciClone development and commercial rights to Vibativ in China

FDA grants orphan drug designation to CRLX-101 for ovarian cancer

FDA accepts amended BLA for Coagadex

Proteostasis Therapeutics discloses USP14 inhibitors

Research at Bristol-Myers Squibb leads to development of new CKI inhibitors

IRAK-4 and TNF-alpha production inhibitors in early development at Takeda

Topline results from phase II study of GS-4774 in virally suppressed patients with chronic HBV

Neurogenesis stimulators described in recent Roche patent

Scynexis patent discloses antiparasitic compounds

FDA approves Viberzi and Xifaxan for IBS-D

Trelagliptin launched in Japan for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....